亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial

医学 易普利姆玛 无容量 内科学 胰腺癌 肿瘤科 无进展生存期 养生 化疗 癌症 维持疗法 临床研究阶段 封锁 外科 胃肠病学 免疫疗法 受体
作者
Kim A. Reiss,Rosemarie Mick,Ursina Teitelbaum,Mark H. O’Hara,Charles Schneider,Ryan Massa,Thomas B. Karasic,Rashmi Tondon,Chioma Onyiah,Mary Kate Gosselin,Alyssa Donze,Susan M. Domchek,Robert H. Vonderheide
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:23 (8): 1009-1020 被引量:132
标识
DOI:10.1016/s1470-2045(22)00369-2
摘要

Background Establishing alternatives to lifelong chemotherapy for patients with advanced pancreatic cancer has been proposed to address chemotherapy resistance and cumulative toxicity. Poly(ADP-ribose) polymerase (PARP) inhibitors have shown efficacy in this setting, and concurrent immune checkpoint blockade could offer synergistic tumour control. The aim of this study was to test the safety and antitumour activity of maintenance with PARP inhibition combined with immune checkpoint blockade in patients with advanced pancreatic cancer who had a stable response to platinum-based chemotherapy. Methods We conducted an open-label, randomised, phase 1b/2 study of niraparib plus anti-PD-1 (nivolumab) or anti-CTLA-4 (ipilimumab) therapy for patients with advanced pancreatic cancer whose cancer had not progressed after at least 16 weeks of platinum-based therapy. Patients were randomly assigned (1:1) via permuted block randomisation (block sizes 2 and 4) to niraparib 200 mg orally per day plus either nivolumab 240 mg intravenously every 2 weeks (later changed to 480 mg intravenously every 4 weeks based on manufacturer update) or ipilimumab 3 mg/kg intravenously every 3 weeks for four doses. The primary endpoints were safety and progression-free survival at 6 months. Treatment groups were not compared for activity, which was assessed in each group against a clinically meaningful progression-free survival at 6 months of 44% (null hypothesis). Superiority of a treatment regimen could be declared if 6-month progression-free survival was 60%, and inferiority if 6-month progression-free survival was 27%. All patients who received at least one dose of study treatment and had at least one post-treatment assessment of response according to Response Evaluation Criteria in Solid Tumours version 1.1 were included in the efficacy population. The safety population consisted of all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03404960, and enrolment is completed and follow-up is ongoing. Findings 91 patients were enrolled between Feb 7, 2018, and Oct 5, 2021 and were randomly assigned to niraparib plus nivolumab (n=46) or niraparib plus ipilimumab (n=45). Of these patients, 84 were evaluable for the progression-free survival endpoint (niraparib plus nivolumab=44; niraparib plus ipilimumab=40). Median follow-up was 23·0 months (IQR 15·0–31·5). 6-month progression-free survival was 20·6% (95% CI 8·3–32·9; p=0·0002 vs the null hypothesis of 44%) in the niraparib plus nivolumab group; and 59·6% (44·3–74·9; p=0·045) in the niraparib plus ipilimumab group. Ten (22%) of 46 patients in the niraparib plus nivolumab group and 23 (50%) of 45 patients in the niraparib plus ipilimumab group had a grade 3 or worse treatment-related adverse event. The most common grade 3 or worse adverse events in the niraparib plus nivolumab group were hypertension (in four [8%] patients), anaemia (two [4%]), and thrombocytopenia (two [4%]) whereas in the niraparib plus ipilimumab group these were fatigue (in six [14%]), anaemia (five [11%]), and hypertension (four [9%]). There were no treatment-related deaths. Interpretation The primary endpoint of 6-month progression-free survival was met in the niraparib plus ipilimumab maintenance group, whereas niraparib plus nivolumab yielded inferior progression-free survival. These findings highlight the potential for non-cytotoxic maintenance therapies in patients with advanced pancreatic cancer. Funding Bristol Myers Squibb, GlaxoSmithKline, the Basser Center Young Leadership Council, The Konner Foundation, The Pearl and Philip Basser Innovation Research Award, the Anonymous Foundation, and the US National Institutes of Health.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
老年学术废物完成签到 ,获得积分10
2秒前
动人的又菡完成签到,获得积分10
2秒前
arniu2008的应助被科研通管家采纳,获得50
5秒前
汉堡包的应助被科研通管家采纳,获得10
5秒前
morena的应助被科研通管家采纳,获得10
5秒前
QXY8P完成签到,获得积分10
5秒前
6秒前
CipherSage的应助被米豆采纳,获得10
9秒前
pp完成签到 ,获得积分10
18秒前
19秒前
缓慢不正完成签到,获得积分10
20秒前
21秒前
pp关注了科研通微信公众号
22秒前
star完成签到 ,获得积分10
23秒前
zhp发布了新的文献求助10
25秒前
27秒前
陌陌完成签到 ,获得积分10
27秒前
Q.curiosity完成签到,获得积分10
28秒前
可靠的公爵熊完成签到,获得积分10
31秒前
cc发布了新的文献求助10
32秒前
时尚的飞阳完成签到,获得积分10
41秒前
煊陌完成签到 ,获得积分10
42秒前
43秒前
bkagyin的应助被千秋采纳,获得10
44秒前
haralee完成签到 ,获得积分0
47秒前
49秒前
51秒前
52秒前
53秒前
fff发布了新的文献求助10
54秒前
Caboda发布了新的文献求助10
55秒前
白rain发布了新的文献求助10
57秒前
米豆发布了新的文献求助10
57秒前
千秋发布了新的文献求助10
59秒前
菜鸟果果完成签到 ,获得积分10
1分钟前
缥缈的鸡翅完成签到,获得积分10
1分钟前
醉熏的孤云完成签到,获得积分10
1分钟前
星辰大海的应助被米豆采纳,获得10
1分钟前
研友_VZG7GZ的应助被纪十三采纳,获得10
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184964
求助须知:如何正确求助?哪些是违规求助? 9573917
关于积分的说明 21833687
捐赠科研通 7782425
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161